OakChart

Legend Biotech Corp ADR

LEGNHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 11:18 AM ET

19.29-1.12 (-5.49%)
2026-11-11 17:18 CET
Market cap
3,954.83 USD m
Revenue, TTM
1,274.56 USD m
Net income, TTM
-91.90 USD m
Free cash flow, TTM
-264.16 USD m
EPS diluted, TTM
-0.51
P/E
-
Compare

Price

LEGN against its 20, 50 and 200-day averages
2050200beatmiss
20.0025.0030.0035.007.3M14.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LEGNclose 19.2920-day 20.8250-day 19.72200-day 22.1919.2952w high52w low

48.6% under the 52-week high of 37.50 on 3 Jun 2026. 52-week low 16.24 on 4 Feb 2026. Last 15 sessions, 32.7% high to low

Profile

LEGN
52-week range, 14% of the way up
16.2437.50

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.

Employees2900
IPOJun 05, 2020
Beta0.56
ATR, 14d1.45
Rel volume1.46
Short float6.44%
Insider own4.60%
Inst own50.80%

Snapshot

6 groups

Valuation

Index-
Market Cap3.74B
Enterprise Value3.05B
Income-91.90M
Sales1.27B
Book/sh6.35
Cash/sh4.98
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2900
IPOJun 05, 2020

Ratios

P/E-
Forward P/E40.57
PEG-
P/S2.93
P/B3.04
P/C3.87
P/FCF-
EV/EBITDA-
EV/Sales2.39
Quick Ratio2.94
Current Ratio3.04
Debt/Eq0.23
LT Debt/Eq0.09
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.51
EPS next Y0.48
EPS next Q0.05
EPS this Y107.28%
EPS next Y706.28%
EPS next 5Y-
EPS past 3/5Y16.80% 6.49%
Sales past 3/5Y106.67% 68.87%
EPS Y/Y TTM71.96%
Sales Y/Y TTM59.59%
EPS Q/Q125.11%
Sales Q/Q51.64%
EarningsNov 10 BMO
EPS/Sales Surpr.10933.33% -0.54%

Ownership

Insider Own4.60%
Insider Trans-0.43%
Inst Own50.80%
Inst Trans-0.29%
ROA-5.34%
ROE-8.11%
ROIC-6.86%
Gross Margin53.00%
Oper. Margin-4.12%
Profit Margin-7.21%
SMA20-7.36%
SMA50-2.17%
SMA200-13.07%
Trades-

Technical

Shs Outstand193.77M
Shs Float184.85M
Short Float6.44%
Short Ratio5.42
Short Interest11.90M
52W High37.50 -48.56%
52W Low16.24 18.77%
Volatility8.96% 6.52%
ATR (14)1.45
RSI (14)43.70
Beta0.56
Rel Volume1.46
Avg Volume2.20M
Volume1,001,722

Performance

Perf Week-15.29%
Perf Month7.88%
Perf Quarter-4.84%
Perf Half Y-32.72%
Perf YTD-11.27%
Perf Year-39.78%
Perf 3Y-70.06%
Perf 5Y-59.77%
Perf 10Y-
Recom1.71
Target Price42.47
Prev Close20.41
Price19.29
Change %-5.49%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 12, 2026DowngradeOOppenheimerOutperform → Perform
Jul 24, 2026DowngradeUUBSBuy → Neutral$28+45.2%
Jul 13, 2026ResumedJJP MorganNeutral$35+81.5%
Feb 12, 2026DowngradeRRothschild & Co RedburnBuy → Neutral$24+24.4%
Jan 22, 2026DowngradeTTD CowenBuy → Hold$21+8.9%
Jan 07, 2026InitiatedOOppenheimerOutperform$75+288.8%
Oct 07, 2025InitiatedCCantor FitzgeraldOverweight$40+107.4%
Oct 08, 2024InitiatedRRedburn AtlanticBuy$86+345.8%
Jun 17, 2024InitiatedTTruistBuy$88+356.2%
May 24, 2024ReiteratedHH.C. WainwrightBuy$86 → $73+278.5%

Peers

Mkt cap
TickerCompanyMkt cap
AUTLAutolus Therapeutics plc ADR331.37M
BMYBristol-Myers Squibb Co126.16B
ALLOAllogene Therapeutics Inc312.55M
GILDGilead Sciences Inc210.78B
IOVAIovance Biotherapeutics Inc3.75B
JNJJohnson & Johnson668.87B
CRBUCaribou Biosciences Inc40.60M
IMTXImmatics N.V1.00B
KYTXKyverna Therapeutics Inc321.45M
CABACabaletta Bio Inc305.24M

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sanders Corazon (Corsee) D.DirectorSep 29 '26Sale9.4627,370258,92052,731Oct 01 04:04 PM
Sanders Corazon (Corsee) D.DirectorSep 29 '26Proposed Sale18.9213,685258,915Sep 29 02:31 PM
Santos Carlos EChief Financial OfficerSep 21 '26Sale9.145,43049,63014,246Sep 23 04:15 PM
Santos Carlos EOfficerSep 22 '26Proposed Sale18.732,71550,854Sep 22 03:30 PM
Huang YingFormer Officer & DirectorSep 22 '26Proposed Sale18.6569,8121,302,109Sep 22 02:33 PM
Casey Patrick JohnDirectorJun 30 '26Proposed Sale29.603,00088,800Jun 30 10:46 AM
Huang YingChief Executive OfficerJun 25 '26Sale14.785,56682,265241,872Jun 29 09:53 PM
Huang YingOfficerJun 26 '26Proposed Sale28.392,78379,017Jun 26 03:23 PM
Huang YingChief Executive OfficerMar 25 '26Sale8.779,93687,139247,438Mar 27 04:25 PM
Huang YingOfficerMar 26 '26Proposed Sale17.544,96887,149Mar 26 04:27 PM
Yeung JessieOfficerMar 26 '26Proposed Sale17.541,86232,663Mar 26 04:20 PM
Huang YingOfficerDec 26 '25Proposed Sale22.5264,3391,449,074Dec 29 07:28 AM
Sanders Corazon (Corsee) D.DirectorDec 24 '25Proposed Sale22.7796922,064Dec 29 06:45 AM
Huang YingOfficerDec 24 '25Proposed Sale22.9561,4671,410,606Dec 29 06:40 AM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
IEMGiShares Core MSCI Emerging Markets ETFAUM: 144.94B
PBEInvesco Biotechnology & Genome ETFAUM: 438.02M
CANCTema Oncology ETFAUM: 217.09M
EEMiShares MSCI Emerging Markets ETFAUM: 28.05B
MCHIiShares MSCI China ETFAUM: 5.77B
GNOMGlobal X Genomics & Biotechnology ETFAUM: 105.76M
IXUSiShares Core MSCI Total International Stock ETFAUM: 57.59B
FBCGFidelity Blue Chip Growth ETFAUM: 7.23B
SPEMState Street SPDR Portfolio Emerging Markets ETFAUM: 16.35B

News

latest 14 of 206
  • LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI Therapy (Stocktwits) -15.97%
  • Legend Biotech's Big EPS Beat Masks Slowing Carvykti Growth And An Effective Guide-Down For Q4 And 2027 (Earnings Whispers)
  • Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights (GlobeNewswire)
  • Legend Biotech to Showcase CARVYKTI Leadership and Next-Generation Cell Therapy Innovation at ASH 2026 (GlobeNewswire) +6.01%
  • How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks (Barrons.com)
  • Loading…
  • Legend Biotech Must Prove Its First Profit Was No Fluke As Margins Reset (Earnings Whispers)
  • Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results (GlobeNewswire) +5.74%
  • Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy (GlobeNewswire)
  • Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma (GlobeNewswire)
  • Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion (GlobeNewswire)
  • LEGNs New CEO From Novartis Paves Way For Buyout Speculation (Stocktwits)
  • Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer (GlobeNewswire)
  • Legend Naming Novartis Executive as CEO (The Wall Street Journal)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-100.130-0.0010.130359.5361.4612
2026Q22026-08-110.0900.0560.090387.5355.9612
2026Q12026-05-12-0.1500.012-0.294305.1306.5112
2025Q42026-03-10-0.0800.001-0.167306.3307.7614
2025Q32025-11-12-0.110-0.073-0.215272.33274.4213
2025Q22025-08-11-0.340-0.114-0.683255.06228.9616
2025Q12025-05-13-0.270-0.210-0.550195.05193.6517
2024Q42025-03-110.070-0.2470.143186.52178.8818
2024Q32024-11-12-0.340-0.330-0.689160.21143.9118
2024Q22024-08-09-0.050-0.287-0.100186.52125.2518
2024Q12024-05-13-0.160-0.194-0.32893.99143.2416
2023Q42024-03-11-0.400-0.356-0.80279.4694.089
2023Q32023-11-20-0.170-0.310-0.34296.0197.2512
2023Q22023-08-15-0.570-0.361-1.12473.3356.649
2023Q12023-05-18-0.340-0.418-0.67736.3442.1810
2022Q42023-03-30-0.332-0.383-0.82227.5836.0613

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-1.280-1.370-2.25875.6851.63
2021FY-1.370-1.559-2.86989.7972.44
2022FY-1.400-1.400-2.803117.01131.97
2023FY-1.470-1.410-2.941285.14297.01
2024FY-0.480-0.840-0.969627.24620.51
2025FY-0.810-0.791-0.8101,0291,030
2026FY-0.051--1,432
2027FY-0.493--1,692
2028FY-0.957--1,912
2029FY-0.794--2,092
2030FY-1.100--2,343

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-101023380.48367.5422.14
2026Q4S2026-11-041032386.02368.9422.14
2026Q4S2026-10-251032386.03368.9422.14
2026Q4S2026-10-131043386.03368.9422.14
2026Q4S2026-10-121034383.86357.95422.14
2026Q4S2026-10-071025383.46357.95422.14
2026Q4S2026-09-281025385.28357.95422.14
2026Q4S2026-09-271024386.92357.95422.14
2026Q4S2026-09-101025386.92357.95422.14
2026Q4S2026-09-081035386.92357.95422.14
2026Q4S2026-08-111035386.92357.95422.14
2026Q4S2026-07-26932400.02364.52450
2026Q4S2026-07-24943400.02364.52450
2026Q4S2026-07-23943400.05364.52450

Estimate history

EPS, annual0.071-0.021-1.009-2.258-2.869-2.803-2.941-0.969-1.615-0.5052
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.1-0.6890.143-0.55-0.683-0.215-0.167-0.2940.172
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual23.67449.08957.36375.12968.917116.866284.895627.5561031.6211274.56
Period201720182019202020212022202320242025TTM
Sales, quarterly186.311161.52185.854195.331255.965272.695307.714306.01388.14
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual132.006132.006132.006133.005154.228165.067181.911183.649184.943193.769
Period201720182019202020212022202320242025MRQ
Shares, quarterly183.171183.451183.649184.029184.571184.69184.943185.74193.769
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,274.561,031.62627.56284.90116.8768.9275.1357.3649.09
Cost of Goods Sold Incl. D&A599.01438.16258.07164.5283.66----
Gross Profit675.55593.47369.49120.3733.21----
Selling, General and Administrative Excl. Other727.69729.32674.79562.20490.72449.51295.45189.3862.83
Research and Development397.18415.80413.75381.89335.25313.76232.56162.2260.58
Other Operating Expense0.331.004.430.000.000.000.000.000.00
Operating Income-52.47-136.86-309.73-441.83-457.51-394.52-230.27-137.29-15.42
Interest Expense22.4721.4621.6321.7810.780.904.220.220.08
Unusual Expense3.210.000.0085.01-21.486.2180.07-0.47-0.09
Net Income Before Taxes-56.48-283.35-158.21-519.67-445.19-407.74-308.82-130.59-1.61
Income Taxes35.4214.2418.90-1.860.62-3.62-41.982.611.17
Consolidated Net Income-91.90-297.58-177.11-517.80-445.82-404.12-266.83-133.20-2.78
Net Income From Continuing Operations-91.90-297.58-177.11-517.80-445.82-404.12-266.83-133.20-2.78
Net Income-91.90-297.58-177.11-517.80-445.82-404.12-266.83-133.20-2.78
EPS (Recurring)-0.46-1.61-0.97-2.60-2.90-2.84-1.78-1.01-0.02
EPS (Basic, Before Extraordinaries)-0.50-1.61-0.97-2.94-2.80-2.87-2.26-1.01-0.02
EPS (Diluted)-0.51-1.61-0.97-2.94-2.80-2.87-2.26-1.01-0.02
EBITDA-6.97-107.88-286.36-421.40-439.14-380.59-220.32-132.02-13.74
Non-Operating Income (Expense)21.68-125.03173.1428.951.62-6.105.756.4413.80
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense37.0548.5851.7335.7325.7215.143.580.960.53
Price To Sales Ratio4.393.889.4837.1967.9495.2644.29--
Gross Margin53.0057.5358.8842.2528.42----
Operating Margin-4.12-13.27-49.35-155.09-391.48-572.46-306.50-239.33-31.41
Net Margin-7.21-28.85-28.22-181.75-381.48-586.38-355.16-232.21-5.67
Shares Outstanding193.77184.94183.65181.91165.07154.23133.01132.01132.01
Market Capitalization3,954.833,954.835,969.5010,938.248,356.767,123.453,717.293,884.94-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue388.14306.01307.71272.69255.96195.33185.85161.52
Cost of Goods Sold Incl. D&A149.35192.07136.02121.58104.2176.6580.4361.44
Gross Profit238.79113.94171.70151.12151.75118.68105.43100.08
Selling, General and Administrative Excl. Other181.00160.68191.38194.63173.71169.40180.11171.01
Research and Development96.1685.96101.77113.3098.65102.07104.0696.31
Other Operating Expense0.000.300.030.000.000.004.410.00
Operating Income57.80-47.04-19.72-43.51-21.96-50.72-79.10-70.93
Interest Expense5.815.525.505.645.245.075.135.55
Unusual Expense0.302.910.000.000.000.970.000.20
Net Income Before Taxes55.59-53.26-19.68-39.13-125.24-99.2740.37-121.88
Income Taxes22.341.2011.260.620.581.7914.184.47
Consolidated Net Income33.25-54.46-30.95-39.74-125.83-101.0626.19-126.35
Net Income From Continuing Operations33.25-54.46-30.95-39.74-125.83-101.0626.19-126.35
Net Income33.25-54.46-30.95-39.74-125.83-101.0626.19-126.35
EPS (Recurring)0.17-0.28-0.17-0.22-0.68-0.550.14-0.69
EPS (Basic, Before Extraordinaries)0.18-0.29-0.17-0.22-0.68-0.550.14-0.69
EPS (Diluted)0.17-0.29-0.17-0.22-0.68-0.550.14-0.69
EBITDA69.51-31.39-7.70-37.40-16.08-45.51-72.33-65.42
Non-Operating Income (Expense)3.912.215.5410.03-98.04-42.51124.60-45.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.0014.5211.2611.280.0011.9810.0130.58
Price To Sales Ratio4.392.933.906.628.188.559.5217.14
Gross Margin61.5237.2355.8055.4259.2960.7656.7261.96
Operating Margin14.89-15.37-6.41-15.96-8.58-25.97-42.56-43.92
Net Margin8.57-17.80-10.06-14.57-49.16-51.7414.09-78.23
Shares Outstanding193.77185.74184.94184.69184.57184.03183.65183.45
Market Capitalization3,954.833,345.624,015.166,018.866,531.196,231.215,969.508,925.92

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments948.601,122.751,309.071,026.92883.82506.07159.18216.432.11
Short Term Receivables250.30124.89157.0645.5258.5582.6235.76108.57228.74
Inventories32.0023.9019.4310.351.751.801.161.130.01
Other Current Assets16.2012.3712.2316.335.713.4611.010.820.03
Total Current Assets1,247.111,283.911,497.801,099.12949.83593.94207.10326.95230.90
Net Property, Plant & Equipment402.00201.59189.68161.67142.95112.1180.0933.122.93
Total Investments and Advances5.004.364.360.004.700.000.000.000.00
Long-Term Note Receivable--0.290.40-----
Intangible Assets1.902.164.063.414.682.850.520.050.00
Deferred Tax Assets-----0.000.0068.924.86
Other Assets77.70178.12152.4266.3717.2713.190.000.000.00
Total Assets1,733.711,670.151,848.611,330.971,119.44722.09287.71429.04238.69
Short Term Debt Incl. Current Port. of LT Debt326.504.793.183.560.911.791.030.630.06
Accounts Payable83.0038.5920.1632.897.044.919.597.324.33
Income Tax Payable19.2020.677.209.779.498.800.0074.549.33
Other Current Liabilities207.70213.59185.88251.56211.76100.07117.1576.7038.39
Total Current Liabilities636.40277.64216.42297.79229.20115.57127.76159.1852.12
Long Term Debt87.20345.81325.50280.97122.051.915.083.940.20
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-----4.24---
Other Liabilities0.000.0048.020.230.400.55277.74257.27174.19
Total Liabilities723.60623.45589.93578.99351.65122.27410.58420.39226.52
Non-Equity Reserves8.006.157.317.661.872.050.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,002.101,040.541,251.37744.31765.93597.77-122.878.6512.17
Total Shareholders Equity1,002.101,040.541,251.37744.31765.93597.77-122.878.6512.17
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,002.101,040.541,251.37744.31765.93597.77-122.878.6512.17
Total Liabilities & Stockholders Equity1,733.711,670.151,848.611,330.971,119.44722.09287.71429.04238.69
Book Value Per Share5.425.676.884.514.974.49-0.930.070.09
Tangible Book Value Per Share5.415.656.864.494.944.47-0.930.070.09
Full-Time Employees2,9002,6091,8261,3871,071882645294-
Price to Book Ratio3.225.358.1717.4015.2613.2611.60--
Return on Assets-17.49-10.07-32.57-36.39-43.92-52.85-37.17-0.83-
Return on Equity-29.14-15.46-51.89-59.04-77.26-112.37--26.73-
Return on Invested Capital-27.32-12.78-32.84-43.48-45.51-44.50--22.0975.96
Quick Ratio1.914.546.833.664.145.121.612.054.43
Current Ratio1.964.626.923.694.145.141.622.054.43

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-56.46-283.35-158.21-519.67-445.19-407.74-308.82-130.59-1.61
Depreciation45.2528.9823.3720.4318.3713.949.955.271.68
Other Funds (Non Cash)75.51247.25-25.16187.7535.2933.0996.54-10.26-11.00
Funds from Operations-27.86-7.12-161.78-312.87-392.06-360.86-202.52-135.78-11.02
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-155.08-93.3520.35-71.26192.28163.19-20.7052.57318.42
Cash from Operating Activities-182.95-100.47-141.42-384.13-199.78-197.67-223.21-83.21307.41
Capital Expenditures-81.21-67.58-69.00-121.40-37.04-47.17-49.86-39.24-21.00
Net Assets From Acquisitions0.000.000.000.00-0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.070.02
Purchase or Sale of Investments412.75779.05-784.95204.40-41.31-148.0725.60-69.66-5.99
Purchase of Investments-992.95-4,554.91-2,713.61-4,858.92-654.19-378.46-72.81-391.07-5.99
Sale Or Maturity of Investments1,405.705,333.971,928.665,063.32612.88230.3998.41321.410.00
Other Uses0.000.000.000.000.000.000.00-13.03-86.86
Other Sources0.000.000.520.910.10-0.0063.1011.93
Cash from Investing Activities331.54711.48-853.4383.90-78.25-195.24-24.26-58.75-101.91
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock214.733.319.72794.55380.12628.92622.550.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock214.733.319.72794.55380.12628.92622.550.000.00
Proceedsfrom Stock Options212.840.000.00782.75377.19624.27621.090.000.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-0.0019.762.72
Other Financing Activities Uses0.000.000.000.000.000.00-0.00-19.26-33.19
Cash from Financing Activities166.87-0.305.70790.80377.53627.49619.9414.692.50
Exchange Rate Effect-1.246.12-2.090.68-2.510.030.620.250.12
Net Change in Cash407.56616.83-991.24491.2596.99234.62373.09-127.02208.12
Free Cash Flow-264.16-168.04-210.42-502.90-235.47-241.63-269.04-121.91286.47
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments964.63834.63948.60992.66967.641,005.46
Short Term Receivables198.01186.61250.30202.57229.00166.85
Inventories41.5037.1032.0029.1835.5930.93
Other Current Assets23.3024.4016.2017.5917.6715.56
Total Current Assets1,227.441,082.731,247.111,242.001,249.901,218.80
Net Property, Plant & Equipment448.21452.51402.00253.74233.60206.58
Total Investments and Advances0.000.005.000.000.000.00
Intangible Assets--1.90-2.142.08
Other Assets75.3061.5077.70217.20204.31188.20
Total Assets1,750.961,596.751,733.711,712.951,689.941,615.66
Short Term Debt Incl. Current Port. of LT Debt168.21277.21326.50150.255.915.34
Accounts Payable77.3074.3083.00102.4575.3658.14
Income Tax Payable33.7020.3019.2010.1111.5514.01
Other Current Liabilities124.40137.30207.70170.76172.67156.88
Total Current Liabilities403.61509.12636.40433.57265.49234.38
Long Term Debt110.00112.1087.20259.99382.01357.47
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities7.707.800.000.000.000.00
Total Liabilities521.32629.02723.60693.56647.50591.85
Non-Equity Reserves0.000.008.008.126.896.06
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,229.64967.731,002.101,011.261,035.561,017.76
Total Shareholders Equity1,229.64967.731,002.101,011.261,035.561,017.76
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,229.64967.731,002.101,011.261,035.561,017.76
Total Liabilities & Stockholders Equity1,750.961,596.751,733.711,712.951,689.941,615.66
Book Value Per Share6.355.215.425.485.615.53
Tangible Book Value Per Share6.355.215.415.485.605.52
Full-Time Employees--2,900---
Price to Book Ratio3.223.343.975.816.425.99
Return on Assets-5.34-15.63-17.48-13.94-18.75-12.94
Return on Equity-8.11-25.28-29.14-22.60-29.80-20.11
Return on Invested Capital2.48-5.04-2.84-3.13-8.88-7.35
Quick Ratio2.942.051.912.804.575.07
Current Ratio3.042.131.962.864.715.20

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income55.66-53.26-19.83-39.04-125.35-99.13
Depreciation11.7115.6512.015.895.885.20
Other Funds (Non Cash)12.3027.7826.778.66147.5664.26
Funds from Operations79.67-9.83-74.39-23.3227.41-30.16
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-100.54-75.52-31.2552.23-40.74-73.59
Cash from Operating Activities-20.87-85.35-105.6428.91-13.33-103.75
Capital Expenditures-20.62-25.98-20.92-13.70-15.61-17.36
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-99.48-142.52661.14-6.39-149.70274.00
Purchase of Investments-270.27-327.98-8.57-386.15-4,060.20-100.00
Sale Or Maturity of Investments170.79185.45669.71379.763,910.51374.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-120.10-168.50640.22-20.08-165.30256.64
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock213.040.100.311.270.281.44
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock213.040.100.311.270.281.44
Proceedsfrom Stock Options212.840.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities168.05-1.20-0.650.67-0.990.67
Exchange Rate Effect-0.30-1.20-2.582.844.461.40
Net Change in Cash26.79-256.26624.7012.34-175.17154.95
Free Cash Flow-41.49-111.33-126.5615.22-28.93-121.11

Revenue breakdown

Pharmaceutical Preparations2024: 627.30M 2025: 1.03B
United States2024: 627.30M 2025: 1.03B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.44%11.9M184.9M2.14M
2026-10-157.52%13.9M184.9M2.34M
2026-09-308.87%16.4M184.8M2.32M
2026-09-157.92%14.6M184.8M2.46M
2026-08-318.92%16.5M184.8M2.72M
2026-08-149.65%17.8M184.8M2.70M
2026-07-3110.26%18.1M176.6M2.82M
2026-07-157.97%14.1M176.6M2.77M
2026-06-307.44%13.1M176.3M2.72M
2026-06-157.37%13.0M176.3M2.38M
2026-05-297.13%12.6M176.2M2.03M
2026-05-158.19%14.4M176.2M2.11M
2026-04-309.54%17.0M178.2M2.01M
2026-04-1510.78%19.2M178.2M2.15M
2026-03-3110.50%18.7M178.2M2.28M
2026-03-1310.09%18.0M178.2M2.40M
2026-02-2711.27%20.0M177.9M2.57M
2026-02-1312.29%21.9M177.9M2.61M
2026-01-3011.84%21.4M180.9M2.41M
2026-01-1510.73%19.4M180.9M2.00M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5014.6018.700.0021.2100.000.000.994-0.0180.000
call5.0012.1016.200.0011.7350.000.000.974-0.0590.002
call7.509.7013.700.008.3040.000.000.962-0.0580.003
call10.007.1011.208.646.3121.000.000.947-0.0560.003
call12.504.608.7010.914.7022.000.000.926-0.0520.004
call15.002.356.304.093.5692.000.000.891-0.0460.006
call17.501.254.105.142.7261800.000.744-0.0600.010
call20.000.200.800.550.8771,70913.000.453-0.0680.012
call22.500.100.500.201.2412,2480.000.246-0.0660.010
call25.000.050.250.051.3481,18427.000.133-0.0490.007
call27.500.002.150.351.6751430.000.113-0.0540.006
call30.000.002.150.301.9802480.000.100-0.0580.005
call32.500.001.400.152.2271700.000.092-0.0610.005
call35.000.002.150.302.44711.000.000.085-0.0640.005
call37.500.002.150.052.6474.000.000.081-0.0660.005
call40.000.002.150.152.82015.000.000.077-0.0680.004
call42.500.002.150.152.9893.000.000.074-0.0700.004
call45.000.002.150.153.1466.000.000.071-0.0720.004
call47.500.002.150.403.9682.000.000.128-0.1390.006
call50.000.002.150.104.1178.000.000.125-0.1410.006
put2.500.000.050.006.2750.000.00-0.005-0.0160.001
put5.000.000.250.004.2020.000.00-0.008-0.0160.001
put7.500.002.150.003.9380.000.00-0.033-0.0490.002
put10.000.002.150.003.7110.000.00-0.075-0.0890.004
put12.500.002.150.002.7180.000.00-0.103-0.0830.006
put15.000.000.250.101.31364.000.00-0.098-0.0380.005
put17.500.000.500.221.0537743.00-0.246-0.0570.010
put20.001.001.901.301.27416758.00-0.547-0.0660.012
put22.501.454.802.902.2491796.00-0.754-0.0640.010
put25.003.906.602.902.1713460.00-0.866-0.0460.007
put27.506.4010.300.003.6800.000.00-0.887-0.0510.006
put30.008.9012.804.503.9851.000.00-0.900-0.0550.005
put32.5011.3015.400.004.4240.000.00-0.908-0.0580.005
put35.0013.8017.906.024.7150.000.00-0.914-0.0600.005
put37.5016.3020.406.604.9250.000.00-0.919-0.0620.005
put40.0018.8022.800.005.1200.000.00-0.923-0.0640.004
put42.5021.3025.300.005.3370.000.00-0.926-0.0650.004
put45.0023.8027.800.005.5360.000.00-0.929-0.0670.004
put47.5026.3030.400.005.8170.000.00-0.931-0.0680.004
put50.0028.8032.900.005.9900.000.00-0.933-0.0690.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-15SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-29144Filing for proposed sale of securities under Rule 144.SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-163Initial statement of beneficial ownership of securities2026-09-15SEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-15SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-18SEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-08-033Initial statement of beneficial ownership of securities2026-07-24SEC
2026-07-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-27SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900308.55K2
2026-080000
2026-070000
2026-060082.27K1
2026-050000
2026-040000
2026-030087.14K1
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC12.49%
DEERFIELD MANAGEMENT COMPANY, L.P.4.38%
MONTANOVA CAPITAL, LLC3.81%
HHLR ADVISORS, LTD.3.22%
BlackRock, Inc.2.54%
WESTFIELD CAPITAL MANAGEMENT CO LP2.39%
Assenagon Asset Management S.A.2.06%
GOLDMAN SACHS GROUP INC1.97%
Point72 Asset Management, L.P.1.66%
Kynam Capital Management, LP1.62%

Funds

Fund% owned
Fidelity OTC Portfolio2.00%
Select Pharmaceuticals Portfolio1.34%
Strategic Advisers Fidelity U.S. Total Stock Fund1.21%
Select Health Care Portfolio1.18%
VIP Contrafund Portfolio1.02%
Fidelity Emerging Markets Fund0.93%
Harbor Small Cap Growth Fund0.73%
SMALLCAP World Fund Inc0.71%
iShares Biotechnology ETF0.57%
Fidelity Advisor Health Care Fund0.55%

OakChart. LEGN. Cached 15 minutes.